Skip to content

Expanded Access to Convalescent Plasma for Treatment of COVID-19

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04472572
Enrollment
Unknown
Registered
2020-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Coronavirus, Covid19, SARS-CoV-2

Brief summary

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Detailed description

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Following enrollment on the protocol and provision of informed consent, patients will be transfused with approximately 200-500 mL of ABO compatible convalescent plasma obtained from individuals who have recovered from documented infection with SARS-CoV-2 and who have been found to have high anti-SARS-CoV2 titers. Safety information collected will include serious adverse events judged to be related to the administration of convalescent plasma. Other information to be collected retrospectively will include patient demographics, resource utilization (total length of stay, days in ICU, days intubated, and survival to discharge from the facility.

Interventions

BIOLOGICALConvalescent Plasma

Fresh or frozen plasma will be infused one time to patients with COVID-19 infection

Sponsors

Hackensack Meridian Health
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Age at least 18 years 2. Laboratory confirmed diagnosis of infection with SARS-CoV-2 3. Admitted to the hospital for the treatment of COVID-19 complications 4. Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease 5. Informed consent provided by the patient or healthcare proxy 6. Severe COVID-19 is defined by one or more of the following: * dyspnea * respiratory frequency ≥ 30/min * blood oxygen saturation ≤ 93% * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 * lung infiltrates \> 50% within 24 to 48 hours Life-threatening COVID-19 is defined as one or more of the following: * respiratory failure/mechanical ventilation * septic shock * multiple organ dysfunction or failure

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026